Search results for " bispecific antibody"

Article A Look at the Affinity Chromatography Landscape
In addition, resins with affinity for many VH3 domain regions are often a good choice for bispecific antibody fragments, while resins with affinity for the kappa light chain may be better alternatives…

Article Advances in Engineering of Protein-Based APIs
Advances in Engineering of Protein-Based APIs New platform technologies, advanced modeling tools, and addressing patient needs are important developments. By Cynthia A. Challener …

Article Get to know: mAb variants - eLearning
The diversity of antibody variants in the biotherapeutics pipeline are increasing with a growing interest for molecules like antibody fragments and bispecific antibodies (bsAbs). Cytiva has p…

Article Process Development: What May Lie Ahead in 2018?
2018 is shaping up to be an interesting year in the world of biopharmaceuticals. What have 2017 developments taught us, and what may lie ahead for biopharmaceutical drug developers and process engin…

Article Best Practices for Selecting a Top-Quality Cell Line
“A balanced plasmid ratio usually has dramatic impact on some formats of bispecific antibody cell line development to minimize impurities,” she explains. Factors such as cell growth and metabolism, as…

Article Process Chromatography: Continuous Optimization
Improved resin chemistries and customized separation solutions are enabling more efficient separations. By Cynthia A. Challener Cell-culture and fermentation are high-…

Article The Challenge of Disruptive Technologies in Bioprocessing
The Challenge of Disruptive Technologies in BioprocessingIncreasing demand for biologics is driving the need for innovation in bioprocessing. Jul 01, 2018 Increasing demand for biologics is drivin…

Article A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
The authors describe the ways in which manufacturers can mitigate the risks related to the integrity of recombinant transgenes expressed in CHO cells. By Luhong He, Christopher Frye Abstract …

Article Scaling Up Novel Therapies
Scaling Up Novel Therapies Platform processes have improved monoclonal antibody scale-up. Can they do the same for personalized therapies? By Agnes S…

Article A Bright Future for the Plasma Fractionation Industry
One example being the announcement from Chugai/Roche in November about the results from studies on “ACE910,” an anti-factor IXa/X humanized bispecific antibody. The third and final day of the co…

Previous PageNext Page